Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241918 | 0.98 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| Hydrochloric Acid SCHEMBL18271203 | 0.96 | ALDH1A1 (0.67) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL20438535 | 0.92 | ALDH1A1 (0.61) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL8099994 | 0.82 | ALDH1A1 (0.64) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL30447073 | 0.82 | ALDH1A1 (0.64) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL11605746 | 0.80 | CYP1A2 (0.75) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL8652657 | 0.80 | ALDH1A1 (0.62) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL11531625 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL10489352 | 0.79 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 | |
| SCHEMBL3717011 | 0.78 | PGR (0.47) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074925-A1 | RARE EARTH COMPLEX | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023282236-A1 | RARE EARTH COMPLEX | 東ソー株式会社 | 2023-01-12 | — | — | WO | disclosed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ALDH1A1 617/4885CYP1A2 1772/4885CYP3A4 1945/4885 |
| US-20250074925-A1 | RARE EARTH COMPLEX | L1CAM, CHRM1, NPM1 | ALDH1A1 2286/4885CYP1A2 1102/4885CYP3A4 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.